| Accession |
PRJCA013637 |
| Title |
To evaluate an open, multicenter, phase Ia/Ib clinical study of SI-B003 bisspecific antibody injection in Chinese patients with advanced solid tumors |
| Relevance |
Medical |
| Data types |
biomarker
|
| Organisms |
Homo sapiens
|
| Description |
An open, multicenter, Phase Ia/Ib clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of SI-B003 bispecial antibody injection in Chinese patients with advanced solid tumors |
| Sample scope |
N/A |
| Release date |
2022-12-05 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Sichuan Baili Pharmaceutical Co., Ltd.
|
|
N/A
|
|
|
|
| Submitter |
tian
du (dutiantian@baili-pharm.com)
|
| Organization |
Sichuan Baili Pharmaceutical Co., Ltd. |
| Submission date |
2022-12-02 |
